Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Interventional × elotuzumab × Clear all

Phase

Phase 2 24 Phase 3 11 Phase 1 7 Phase 1/2 6 Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 51 Cyclophosphamide 46 pembrolizumab 33 fludarabine 31 Radiotherapy 26 Biopsy 23 Nivolumab 22 Metformin 20 Bevacizumab 19 Fluorodeoxyglucose F18 18 Specimen Handling 17 Cisplatin 14 Radiosurgery 13 Carboplatin 13 Paclitaxel 12 Temozolomide 11 Fluorouracil 11 Dexamethasone 11 durvalumab 10 Rituximab 10 Gemcitabine 10 atezolizumab 9 X-Rays 9 Radiation 9 Letrozole 9 Immunotherapy, Adoptive 9 Etoposide 9 Doxorubicin 9 olaparib 8 gallium Ga 68 dotatate 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05560399 2026-01-02

CC-220

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡